Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ameliorating Contrast Induced Nephropathy After Coronary Angiography
NCT06139952Phase 4Completed
- Sponsor
- Ain Shams University
- Start
- Dec 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of atorvastatin and acetylcysteine in contrast-induced nephropathy (CIN) (3 arms), sponsored by Ain Shams University. Primary endpoint: Contrast induced nephropathy incidence. Started Dec 2023; status: completed.
02
Drugs
atorvastatinacetylcysteine
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NCT06139952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06139952.